

**THEROS PHARMA LTD**

**Company Registration Number:  
08042529 (England and Wales)**

**Unaudited abridged accounts for the year ended 28 April 2019**

**Period of accounts**

**Start date: 01 May 2018**

**End date: 28 April 2019**

# **THEROS PHARMA LTD**

## **Contents of the Financial Statements for the Period Ended 28 April 2019**

Balance sheet

Notes

# THEROS PHARMA LTD

## Balance sheet

As at 28 April 2019

	<i>Notes</i>	<i>2019</i>	<i>2018</i>
		<b>£</b>	<b>£</b>
<b>Fixed assets</b>			
Tangible assets:	3	0	2,150
Investments:	4	0	87,944
<b>Total fixed assets:</b>		<u>0</u>	<u>90,094</u>
<b>Current assets</b>			
Debtors:		14	249,752
Cash at bank and in hand:		12	52,390
<b>Total current assets:</b>		<u>26</u>	<u>302,142</u>
Creditors: amounts falling due within one year:		0	(6,454)
<b>Net current assets (liabilities):</b>		<u>26</u>	<u>295,688</u>
Total assets less current liabilities:		26	385,782
<b>Total net assets (liabilities):</b>		<u>26</u>	<u>385,782</u>
<b>Capital and reserves</b>			
Called up share capital:		1,000	100
Profit and loss account:		(974)	385,682
<b>Shareholders funds:</b>		<u>26</u>	<u>385,782</u>

The notes form part of these financial statements

# **THEROS PHARMA LTD**

## **Balance sheet statements**

For the year ending 28 April 2019 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company's profit & loss account.

**This report was approved by the board of directors on 19 August 2020  
and signed on behalf of the board by:**

Name: M Barnes  
Status: Director

The notes form part of these financial statements

# **THEROS PHARMA LTD**

## **Notes to the Financial Statements**

**for the Period Ended 28 April 2019**

### **1. Accounting policies**

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

#### **Turnover policy**

The turnover represents the value of all services delivered during the period, at selling price exclusive of Value Added Tax. Sales are recognised at the point at which the company has fulfilled its contractual obligations to the customer.

#### **Tangible fixed assets and depreciation policy**

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses. Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases: Computer equipment 25 per cent reducing balance

#### **Other accounting policies**

**Taxation** The tax expense represents the sum of the deferred tax expense. Current tax assets are recognised when tax paid exceeds the tax payable. Deferred tax is charged or credited to profit or loss, except when it relates to items charged or credited to other comprehensive income or equity, when the tax follows the transaction or event it relates to and is also charged or credited to other comprehensive income, or equity. Deferred tax assets and deferred tax liabilities are offset, if and only if, there is a legally enforceable right to set off the amounts and the entity intends either to settle on the net basis or to realise the asset and settle the liability simultaneously. Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events that result in an obligation to pay more tax in the future or a right to pay less tax in the future have occurred at the balance sheet date. Timing differences are differences between the company's taxable profits and its results as stated in the financial statements that arise from the inclusion of gains and losses in tax assessments in periods different from those in which they are recognised in the financial statements. Deferred tax is measured at the average tax rates that are expected to apply in the periods in which timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date. Deferred tax is measured on a non-discounted basis.

# **THEROS PHARMA LTD**

## **Notes to the Financial Statements for the Period Ended 28 April 2019**

### **2. Employees**

	<i>2019</i>	<i>2018</i>
Average number of employees during the period	1	1

# THEROS PHARMA LTD

## Notes to the Financial Statements for the Period Ended 28 April 2019

### 3. Tangible Assets

	Total
<b>Cost</b>	£
At 01 May 2018	2,380
Disposals	(2,380)
At 28 April 2019	<u>0</u>
<b>Depreciation</b>	
At 01 May 2018	230
Charge for year	595
On disposals	(825)
At 28 April 2019	<u>0</u>
<b>Net book value</b>	
At 28 April 2019	<u>0</u>
At 30 April 2018	<u>2,150</u>

# **THEROS PHARMA LTD**

## **Notes to the Financial Statements**

**for the Period Ended 28 April 2019**

### **4. Fixed investments**

Interests in investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in profit or loss. Transaction costs are expensed to profit or loss as incurred.

# **THEROS PHARMA LTD**

## **Notes to the Financial Statements**

**for the Period Ended 28 April 2019**

### **5. Financial commitments**

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases of £nil (2018 - £17,985).

# **THEROS PHARMA LTD**

## **Notes to the Financial Statements**

**for the Period Ended 28 April 2019**

### **6. Related party transactions**

Name of the related party:	Director	
Relationship:	Director	
Description of the Transaction:	Directors loan account	
		£
Balance at 01 May 2018		882
Balance at 28 April 2019		<b>0</b>

Name of the related party:	Connected companies	
Relationship:	Connected companies	
Description of the Transaction:	Amounts due from connected companies	
		£
Balance at 01 May 2018		228,025
Balance at 28 April 2019		<b>0</b>

Dividends totalling £70,000 (2018 - £37,000) were paid in the period in respect of shares held by the company director. During the period investments of £96,328 and other debtors of £228,025 were reassigned to a connected company.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.